A study commissioned by three of the UK’s leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.
In the highest value deal yet seen for a preclinical pipeline, GlaxoSmithKline plc swooped on Domantis Ltd, paying £230 million cash for the six-year-old UK Medical Research Council spin out.